NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$29.42

+0.46 (+1.59%)

(As of 05/26/2023 08:47 PM ET)

Compare

Today's Range: $28.36
▼
$29.51
50-Day Range: $26.24
▼
$34.92
52-Week Range: $13.15
▼
$39.85

Volume: 265,500 shs
Average Volume: 497,654 shs
Market Capitalization: $1.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.22

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 60.5% Upside
$47.22 Price Target
Short Interest: Bearish
21.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 8 Articles This Week
Insider Trading: Selling Shares
$42,470 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.66) to ($3.11) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

866th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

140th out of 169 stocks

3.3

Analyst's Opinion

Consensus Rating
Kymera Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.22, Kymera Therapeutics has a forecasted upside of 60.5% from its current price of $29.42.
Amount of Analyst Coverage
Kymera Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
21.28% of the float of Kymera Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Kymera Therapeutics has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Kymera Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Kymera Therapeutics does not currently pay a dividend.
Dividend Growth
Kymera Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KYMR.

2.6

News and Social Media Coverage

News Sentiment
Kymera Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Kymera Therapeutics this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for KYMR on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,470.00 in company stock.
Percentage Held by Insiders
17.01% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.66) to ($3.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kymera Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kymera Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kymera Therapeutics has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Stock News Headlines

May 22, 2023 | markets.businessinsider.com

Kymera Appoints Jeremy Chadwick As COO

May 22, 2023 | msn.com

Kymera Therapeutics appoints COO

May 29, 2023 | Stocks To Trade (Ad)

3 Free Stock Picks per Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 22, 2023 | finance.yahoo.com

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

May 19, 2023 | finance.yahoo.com

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

May 18, 2023 | finance.yahoo.com

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 14, 2023 | seekingalpha.com

Kymera: More Data Needed

May 12, 2023 | americanbankingnews.com

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $47.22

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 10, 2023 | americanbankingnews.com

Brokers Set Expectations for Kymera Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KYMR)

May 9, 2023 | finance.yahoo.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript

May 8, 2023 | markets.businessinsider.com

Kymera Therapeutics (KYMR) Gets a Buy from H.C. Wainwright

May 8, 2023 | americanbankingnews.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Raymond James to Outperform

May 5, 2023 | msn.com

Credit Suisse Maintains Kymera Therapeutics (KYMR) Neutral Recommendation

May 5, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Hold Rating on Kymera Therapeutics (KYMR)

May 5, 2023 | msn.com

Raymond James Upgrades Kymera Therapeutics (KYMR)

May 5, 2023 | msn.com

Kymera Therapeutics Surges on New Analyst Love

May 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Integra Lifesciences (IART) and Kymera Therapeutics (KYMR)

May 4, 2023 | finance.yahoo.com

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates

May 4, 2023 | finanznachrichten.de

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

May 4, 2023 | finance.yahoo.com

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023 | americanbankingnews.com

Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday

April 19, 2023 | finance.yahoo.com

Some Shareholders Feeling Restless Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) P/S Ratio

April 11, 2023 | finance.yahoo.com

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

April 8, 2023 | americanbankingnews.com

Kymera Therapeutics (NASDAQ:KYMR) and Novavax (NASDAQ:NVAX) Financial Survey

March 25, 2023 | americanbankingnews.com

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $47.22

March 12, 2023 | benzinga.com

Kymera Therapeutics Stock (NASDAQ:KYMR), Short Interest Report

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings: 5/04/2023
Today: 5/28/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KYMR
CUSIP: N/A
CIK: 1815442
Web: www.kymeratx.com
Phone: 857-285-5300
Fax: N/A
Employees: 141
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $47.22
High Stock Price Forecast: $85.00
Low Stock Price Forecast: $31.00
Forecasted Upside/Downside: +60.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-154,810,000.00
Net Margins: -340.80%
Pretax Margin: -340.80%
Return on Equity: -34.15%
Return on Assets: -26.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.65
Quick Ratio: 6.65

Sales & Book Value

Annual Sales: $46.83 million
Price / Sales: 34.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.35 per share
Price / Book: 3.52

Miscellaneous

Outstanding Shares: 55,310,000
Free Float: 45,900,000
Market Cap: $1.63 billion
Optionable: Not Optionable
Beta: 1.71

Key Executives

Dr. Bruce L. Booth D.Phil. (Age 49)
DPHIL, Ph.D., Co-Founder & Chairman
Comp: $73k

Dr. Nello Mainolfi M.D. (Age 44)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $940.11k

Mr. Bruce N. Jacobs CFA
Chief Financial Officer

Dr. Jared A. Gollob M.D. (Age 58)
Chief Medical Officer
Comp: $676.75k

Ms. Elaine Caughey
Chief Bus. Officer

Kevin Dushney
Sr. VP of IT & Operations

Mr. Michael J. Todisco (Age 58)
VP of Accounting & Fin.

Mr. Vijay Sabesan (Age 51)
Sr. VP of Technical Operations

Ms. Melissa Brody
VP of Bus. Devel.

Ms. Karen Weisbach
VP of People & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.
What is Kymera Therapeutics' stock price forecast for 2023?: 8 brokerages have issued 12-month target prices for Kymera Therapeutics' shares. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's share price to reach $47.22 in the next year. This suggests a possible upside of 60.5% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.
How have KYMR shares performed in 2023?: Kymera Therapeutics' stock was trading at $24.96 at the beginning of the year. Since then, KYMR shares have increased by 17.9% and is now trading at $29.42.
View the best growth stocks for 2023 here.
When is Kymera Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our KYMR earnings forecast.
How were Kymera Therapeutics' earnings last quarter?: Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.01. The firm had revenue of $9.47 million for the quarter, compared to analysts' expectations of $14.15 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.15% and a negative net margin of 340.80%. The business's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.71) earnings per share.
What ETFs hold Kymera Therapeutics' stock?: ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Simplify Propel Opportunities ETF (SURI), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and Invesco Nasdaq Biotechnology ETF (IBBQ).
What other stocks do shareholders of Kymera Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?: (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.
What is Kymera Therapeutics' stock symbol?: Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."
Who are Kymera Therapeutics' major shareholders?: Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (10.59%), BVF Inc. IL (8.57%), Price T Rowe Associates Inc. MD (8.44%), Wellington Management Group LLP (7.76%), Avoro Capital Advisors LLC (6.97%) and BlackRock Inc. (6.02%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.
How do I buy shares of Kymera Therapeutics?: Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kymera Therapeutics' stock price today?: One share of KYMR stock can currently be purchased for approximately $29.42.
How much money does Kymera Therapeutics make?: Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $1.63 billion and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.
How many employees does Kymera Therapeutics have?: The company employs 141 workers across the globe.
How can I contact Kymera Therapeutics?: Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

Kymera Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kymera Therapeutics (NASDAQ:KYMR) Stock

KYMR Stock News Headlines

KYMR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KYMR Stock - Frequently Asked Questions

Overall MarketRank^™